Targeting the transcription factor NRF2 has been recognized as a feasible strategy for cancer prevention and treatment, but many of the mechanistic details underlying its role in cancer development and progression are lacking. Therefore, careful mechanistic studies of the NRF2 pathway in cancer initiation and progression are needed to identify which therapeutic avenue-activation or inhibition-is appropriate in a given context. 
Cancer is the second leading cause of death in the United States (US) and worldwide. 1 Lung cancer is the most common cancer in the United
States (excluding melanoma) with an estimated 158 000 deaths in 2016, which accounts for 27% of all cancer deaths, and makes it the leading cause of cancer deaths. 2 Non-small cell lung cancer (NSCLC) makes up ∼85% of all diagnosed cases of lung cancer, and has a predicted 5-year survival rate of 15.9%. 3 Recent studies have also identified a high prevalence of mutations in genes of the nuclear factor erythroid 2-related factor 2 (NRF2) pathway that result in uncontrolled, constitutive activation of NRF2 in NSCLC. 4, 5 NRF2 is the primary regulator of cellular redox homeostasis and xenobiotic metabolism. 6 Through its role as a transcription factor, NRF2 controls the expression of antioxidant response element (ARE) regulated genes. 7 NRF2 target genes can be classified into: drug metabolizing enzymes (phase I-III), redox proteins, transcription factors, antiapoptotic proteins, carbohydrate and lipid metabolizing enzymes, proliferation and cell cycle regulators, proteostasis machinery (autophagy and proteasomal), and heme and iron metabolizing proteins. 8, 9 NRF2 is expressed in all human organs, but its basal levels under homeostatic conditions are low due to tight regulatory mechanisms that continuously target it for degradation in the cytosol. This is achieved by association of NRF2 with Kelch-like ECHassociated protein 1 (KEAP1), the main regulator of NRF2, which serves as an E3 ubiquitin ligase substrate adaptor protein. 10 KEAP1
dimers interact with the N-terminal Neh2 domain of NRF2, thus bringing it in close proximity to the Cullin 3-RING Box 1 (CUL3-RBX1) E3 ubiquitin ligase. 11, 12 As a result, NRF2 is ubiquitylated and subsequently degraded by the 26S proteasome. However, under oxidative stress, critical cysteine residues in KEAP1 get oxidized, which affects its conformation, thereby leading to an NRF2-KEAP1 complex that does not favor ubiquitylation. 13 As a consequence, this protein complex is stabilized and newly synthesized NRF2 accumulates and translocates to the nucleus, where it dimerizes with a small MAF protein and performs its transcriptional function. 7 Upon restoration of redox balance, KEAP1 translocates into the nucleus to escort NRF2 back into the cytosol and restore it to basal levels. 14 This mechanism of controlled NRF2 regulation is operative in the canonical NRF2 pathway. 15 Numerous studies have demonstrated that Nrf2 −/− mice are more susceptible than wild type mice to chemically induced carcinogenesis, 16, 17 in agreement with the observation that canonical NRF2 activation by chemopreventive compounds, such as sulforaphane (SF), prevent carcinogenesis. 18 However, NRF2 has a dark side in cancer, as uncontrolled activation of NRF2 aids in the promotion, progression, and metastasis of cancer; contributes to chemo and radiotherapy resistance; and confers a poor prognosis. 15, [19] [20] [21] [22] NRF2 was modulated after tumor development. Our results support this overall conclusion: NRF2 prevents the initiation of environmental factor-induced cancer but has no effect on spontaneous cancer arising from oncogene activation. Furthermore, NRF2 promotes the progression of pre-existing tumors, while NRF2 inhibition reduces pre-existing tumor growth in both models. were sacrificed at 15 weeks, as described previously. 41 For the genetic model, LSL-K-ras G12D/+ mice were obtained from The Jackson Laboratory. 42 Mice were intratracheally instilled with Cre adenovirus to activate expression of the Kras G12D oncogene. These mice were sacrificed 6 weeks after the start of the experiment. See Figure 1 for a detailed description of treatment schedules. Mice were weighed once a week for the duration of the experiments. At the time of euthanasia, lungs were collected for gross analysis of total surface tumors and weight. Then, the lungs were divided and were either fixed in neutral buffered formalin for histological analyses or snap frozen for protein and RNA analyses.
| Immunoblot analyses
Lung tissues were homogenized in sample buffer containing 50 mM
Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, and 100 mM dithiothreitol (DTT). Lysates were boiled for 10 min and sonicated. Lysates were resolved by SDS-PAGE, transferred onto a nitrocellulose membrane, and subjected to immunoblot analyses with the indicated antibodies. The relative intensity of the bands was quantified using the ChemiDoc CRS gel documentation system and Quantity One software (Biorad, Hercules, CA).
| Histological analyses
Staining was performed using the EnVision + System-HRP kit (DakoAgilent, Santa Clara, CA) according to the manufacturer's instructions and nuclei were counterstained with hematoxylin. Images were acquired using a Nikon Eclipse 50i microscope with the NIS Elements F software.
H&E images were acquired using a 2X objective and images were superimposed to compose a whole lung image using Photoshop 7.0. Tissue sections were incubated with TUNEL reaction mixture for 1 h at 37°C in the dark and nuclei were counterstained with Hoechst.
Slides were analyzed using a Zeiss Observer. Z1 microscope with the Slidebook 5.0 software (Intelligent Imaging Innovations, Inc., Oberkochen, Germany).
| Statistical analyses
The results are presented as fold changes to the NTC group. Data are all shown as mean ± SEM (n = 5). Statistical tests were performed using SPSS 20.0. Unpaired student's t-tests were used to compare the means of two groups. One-way analysis of variance was applied to compare the means of three or more groups. P < 0.05 was considered to be significant. In the Kras G12D model, SF or Bru pre-treatment did not affect NRF2 or KRAS signaling, compared to the NTC group ( Figure 3D-F) , which is consistent with the result showing that pre-treatment had no effects on tumor burden ( Figures 2G and 2J) . SF post-treatment increased NRF2 signaling and ERK phosphorylation, while Bru Total lung tissue lysates of mice (n = 3/group) from the VC model (A) and the Kras model (D) were subjected to immunoblot analyses with the indicated antibodies. (B and E) Band intensities were quantified and normalized to the loading control (GAPDH) to obtain relative protein levels for the VC model (B) and the Kras model (E). The relative protein level in the NTC group was set to 1, and the relative protein levels in other groups were normalized to the NTC group. Results are presented as means ± SD. *P < 0.05 compared to NTC. C and F, mRNA expression of the indicated genes in the NRF2 and KRAS pathways. Total RNA extracted from lung tissue (n = 3/group) from the VC model (C) and the Kras model (F) was subjected to qRT-qPCR analysis. Results are presented as means ± SD. *P < 0.05 compared to NTC post-treatment reduced NRF2 signaling and p-ERK (Figure 3D-F) . As expected, none of the treatments affected KEAP1 (mRNA or protein levels were measured, Figure 3D -F), as well as the total protein levels of ERK or KRAS ( Figures 3D and 3E ). these results demonstrate that this activation is not maximized and can be further enhanced by SF, thus increasing proliferation and the growth rate of these tumors. Bru-post was again proven effective as an anti-cancer intervention. Our current study showed that Bru alone was also an effective anticancer agent, but we and others have shown that Bru is most effective in combination with chemotherapy. 30, 31, 37 Although Bru was recently found to be a global protein translation inhibitor, it has a very strong inhibitory effect on NRF2 due to NRF2's short protein half-life. 44 Even though it is unlikely that Bru will become a drug for cancer treatment, it still serves as an important research tool and provides proof-of-concept demonstrating the effectiveness of NRF2 inhibition for cancer treatment while new specific NRF2 inhibitors are being developed.
Our results rekindle the debate over NRF2 activation for cancer prevention. While pre-activation of NRF2 is a very powerful means to prevent cancer induced by environmental carcinogen exposure, presumably by blocking cancer initiation, activation of NRF2 once cancer has developed was detrimental in both the chemical and genetic models. It has been widely speculated that the failure of antioxidants in human clinical trials might be due to the promotion of preexisting malignancies, 45 which may be true for compounds that induce NRF2, as seen in our results for SF post-treatment in both models. Therefore, while increases in the consumption of natural products containing NRF2 inducers in healthy populations could greatly reduce cancer incidence, it might be unadvisable in cancer patients. To further support the importance of NRF2 activation for chemoprevention, key studies by Yamamoto's group found that systemic NRF2 activation enhances antitumor immunity and prevents metastasis in Keap1 −/− mice. 46, 47 Antitumor immunity is largely dependent on CD8 + T cells and macrophages, 48 and a study has
shown that NRF2 activation in macrophages is necessary for CD8 + T cell function. 
